Indication |
For use in the treatment of subacute or chronic angle-closure
glaucoma after iridectomy or where surgery is refused or
contraindicated. |
Pharmacodynamics |
Echothiophate Iodide is a potent, long-acting cholinesterase
inhibitor used as a miotic in the treatment of glaucoma. Echothiophate
iodide will depress both plasma and erythrocyte cholinesterase levels in
most patients after a few weeks of eyedrop therapy. |
Mechanism of action |
Echothiophate Iodide is a long-acting cholinesterase inhibitor for
topical use which enhances the effect of endogenously liberated
acetylcholine in iris, ciliary muscle, and other parasympathetically
innervated structures of the eye. Echothiophate iodide binds
irreversibly to cholinesterase, and is long acting due to the slow rate
of hydrolysis by cholinesterase. It causes miosis, increase in facility
of outflow of aqueous humor, fall in intraocular pressure, and
potentiation of accommodation. |
Absorption |
Not Available |
Volume of distribution |
Not Available |
Protein binding |
Not Available |
Metabolism |
Not Available |
Route of elimination |
Not Available |
Half life |
Not Available |
Clearance |
Not Available |
Toxicity |
Side effects include blurred vision or change in near or distant vision and eye pain. |
Comments
Post a Comment